Mineralocorticoid receptor antagonists

Hari Krishnan Parthasarathy; Thomas M. MacDonald

doi:10.1007/s11906-007-0009-3

Mineralocorticoid receptor antagonists

Hari Krishnan Parthasarathy, Thomas M. MacDonald

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of mineralocorticoid receptor antagonists has provided clinicians with an important tool towards complete blockade of the renin-angiotensin-aldosterone axis.

Original language	English
Pages (from-to)	45-52
Number of pages	8
Journal	Current Hypertension Reports
Volume	9
Issue number	1
DOIs	https://doi.org/10.1007/s11906-007-0009-3
Publication status	Published - Mar 2007

Keywords

SELECTIVE ALDOSTERONE BLOCKER
LEFT-VENTRICULAR HYPERTROPHY
RANDOMIZED ALDACTONE EVALUATION
CONGESTIVE-HEART-FAILURE
ESSENTIAL-HYPERTENSION
MYOCARDIAL-INFARCTION
IN-VIVO
SPIRONOLACTONE
EPLERENONE
EFFICACY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11906-007-0009-3

Cite this

@article{32bb50a3104d45119ddfc2a2720ce69e,

title = "Mineralocorticoid receptor antagonists",

abstract = "With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of mineralocorticoid receptor antagonists has provided clinicians with an important tool towards complete blockade of the renin-angiotensin-aldosterone axis.",

keywords = "SELECTIVE ALDOSTERONE BLOCKER, LEFT-VENTRICULAR HYPERTROPHY, RANDOMIZED ALDACTONE EVALUATION, CONGESTIVE-HEART-FAILURE, ESSENTIAL-HYPERTENSION, MYOCARDIAL-INFARCTION, IN-VIVO, SPIRONOLACTONE, EPLERENONE, EFFICACY",

author = "Parthasarathy, {Hari Krishnan} and MacDonald, {Thomas M.}",

year = "2007",

month = mar,

doi = "10.1007/s11906-007-0009-3",

language = "English",

volume = "9",

pages = "45--52",

journal = "Current Hypertension Reports",

issn = "1522-6417",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Mineralocorticoid receptor antagonists

AU - Parthasarathy, Hari Krishnan

AU - MacDonald, Thomas M.

PY - 2007/3

Y1 - 2007/3

N2 - With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of mineralocorticoid receptor antagonists has provided clinicians with an important tool towards complete blockade of the renin-angiotensin-aldosterone axis.

AB - With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of mineralocorticoid receptor antagonists has provided clinicians with an important tool towards complete blockade of the renin-angiotensin-aldosterone axis.

KW - SELECTIVE ALDOSTERONE BLOCKER

KW - LEFT-VENTRICULAR HYPERTROPHY

KW - RANDOMIZED ALDACTONE EVALUATION

KW - CONGESTIVE-HEART-FAILURE

KW - ESSENTIAL-HYPERTENSION

KW - MYOCARDIAL-INFARCTION

KW - IN-VIVO

KW - SPIRONOLACTONE

KW - EPLERENONE

KW - EFFICACY

U2 - 10.1007/s11906-007-0009-3

DO - 10.1007/s11906-007-0009-3

M3 - Article

SN - 1522-6417

VL - 9

SP - 45

EP - 52

JO - Current Hypertension Reports

JF - Current Hypertension Reports

IS - 1

ER -

Mineralocorticoid receptor antagonists

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this